Why Sickle Cell Disease first.
Every year, 515,000 babies are born with Sickle Cell Disease, 80% in Sub-Saharan Africa. Today, 7.74 million people worldwide live with the disease.
It is the founding programme of the African Genome Project
— not because it is the only disease that matters, but because it gives us an opportunity to understand why the disease affects people so differently, how they respond to treatment, and how to better predict their outcomes, while building the clinical, genomic, and interpretation infrastructure needed to answer these questions at scale.
African genomes deserve African reference data.
We sequence and clinically characterise every participant, then return a personalised pharmacogenomic report built around genetic variation that conventional European reference panels can overlook or misclassify.
By interpreting African genomes against African data, we turn genetic diversity into clinical insight, and insight into better-informed care.
